Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions

摘要

AimThe aim of the present study was to analyse concomitant drug use and its association with outcome in patients (N=17701) receiving rivaroxaban or standard of care (SOC) for the prevention of venous thromboembolism after major orthopaedic surgery in the non-interventional, phase IV XAMOS (Xarelto (R) in the prophylaxis of post-surgical venous thromboembolism after elective major orthopaedic surgery of hip or knee) study.